CVS Caremark is set to implement a new strategy that could deliver a blow to drugmakers' pricing power, according to a Fierce Pharma report. The pharmacy benefit manager is planning to let clients cite drug review assessments by the Institute of Clinical and Economic Review to exclude drugs. The […]
Report: Eli Lilly Ignoring California’s Price Hike Notice Law
Eli Lilly is reportedly ignoring a California law which requires drugmakers to both announce and justify prescription drug price hikes months in advance, according to a Los Angeles Times report. The company says it's waiting for a court decision on an industry lawsuit challenging the […]
Express Scripts Blocks 48 Drugs
Pharmacy benefit manager Express Scripts reportedly blocked 48 drugs from its formulary, according to a Fierce Pharma report. The drugs include 22 competitors to generics, 12 that include the same active ingredient with a lower net cost and 11 that have a lower-cost brand or biosimilar […]
AMCP Forum Spotlights Payment, Benefit Models for High-Cost Drugs
The Academy of Managed Care Pharmacy hosted a multi-stakeholder meeting last week in Baltimore at which attendees discussed some payment models health care payers could incorporate as high-cost treatments enter the market each year. The AMCP Partnership Forum, titled "Designing benefits and Payment […]
Experts: Drug Price Freezes Unlikely to Bring Lower Out-Of-Pocket Costs
Experts say recent price freezes by pharmaceutical companies are unlikely to result in lower out-of-pocket costs, according to a Time report. Pfizer, Novartis, Bayer are among the drugmakers who have said they will freeze prices on some of their drugs for the remainder of 2018. Merck & Co. […]
Regeneron Takes Fight to Drug Pricing System
"It's not simply about just growing your earnings per share by raising your prices," Regeneron Pharmaceuticals Cofounder Leonard Schleifer tells Forbes. Schleifer has an axe to grind with the current drug pricing practices by pharmaceutical companies in the U.S., and says he's taking active steps […]
The 7 Most Out-of-Reach Drugs
A recent Modern Healthcare Executive report takes a look at the seven most out-of-reach drugs as a result of their high costs. Biologics, according to West Monroe Partners Senior Director and Leader of Life Sciences Ed Francis tells MHE says while biologic prices will come down, they ultimately […]
Article: Trump Browbeating Pharma on Prices
Trump administration officials are taking a hard line on high drug prices as the administration continues to put pressure on the pharmaceutical industry. According to a New York Times report, Health and Human Services Deputy Secretary Eric Hargan told the board of the Pharmaceutical Research and […]
Engelberg: Taxpayers Deserve Reasonable Drug Prices for Federally-Funded Drug Development
Alfred Engelberg, an Engelberg Foundation trustee, says U.S. taxpayers should not be forced to pay exorbitant prices on drugs discovered using federal funding. Engelberg in a commentary published on Modern Healthcare says the pharmaceutical industry has for some time made less significant […]
Merck Avoids Lowering Cost of Blockbuster Products
While drugmaker Merck & Co. announced Thursday it would be cutting back the prices on some of its drugs, none of its major, top-selling cancer and diabetes treatments will see any lower costs, the New York Times reports. Among the drugs receiving price cuts, Zepatier, a hepatitis C drug, will […]
